Viking Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Viking Therapeutics has a total shareholder equity of $911.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $937.9M and $26.4M respectively.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$930.44m |
| Aandelen | US$911.45m |
| Totaal verplichtingen | US$26.44m |
| Totaal activa | US$937.89m |
Recente financiële gezondheidsupdates
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Recent updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09
Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Analyse van de financiële positie
Kortlopende schulden: VKTX's short term assets ($936.6M) exceed its short term liabilities ($25.7M).
Langlopende schulden: VKTX's short term assets ($936.6M) exceed its long term liabilities ($755.0K).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: VKTX is debt free.
Schuld verminderen: VKTX had no debt 5 years ago.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: VKTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Voorspelling contante baan: VKTX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25% each year